Lino-M Tablet 2.5 mg + 500 mg is a combination oral antidiabetic medication containing Linagliptin and Metformin Hydrochloride. It is designed to improve blood glucose control in adults with type 2 diabetes mellitus, particularly in patients whose blood sugar levels are not adequately managed with diet, exercise, or monotherapy.

Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin hormone levels, enhancing insulin release and suppressing glucagon secretion in a glucose-dependent manner. Metformin Hydrochloride, a biguanide, reduces hepatic glucose production and improves insulin sensitivity, promoting better peripheral glucose uptake.

The combination provides complementary mechanisms of action, targeting both insulin deficiency and insulin resistance. Lino-M offers effective glycemic control while reducing the risk of hypoglycemia compared to some other antidiabetic therapies.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Oral Antidiabetic – DPP-4 Inhibitor + Biguanide Combination

Indications

Lino-M Tablet 2.5 mg + 500 mg is indicated for:

• Type 2 Diabetes Mellitus: as an adjunct to diet and exercise in adults

• For patients inadequately controlled on:

  • Metformin alone

  • Linagliptin alone

  • Other oral antidiabetic agents where dual therapy is appropriate

• Reducing postprandial and fasting plasma glucose levels

• May be used in combination with insulin or other antidiabetic medications under physician supervision

This dual therapy is particularly useful for patients requiring better blood sugar control without increasing the risk of significant weight gain or hypoglycemia.

Pharmacology

Linagliptin:

• Inhibits the enzyme DPP-4, which degrades incretin hormones (GLP-1 and GIP)

• Increases insulin secretion in response to meals

• Suppresses glucagon release from the pancreas, reducing hepatic glucose production

Metformin Hydrochloride:

• Reduces hepatic gluconeogenesis (glucose production by the liver)

• Enhances insulin sensitivity, promoting glucose uptake in peripheral tissues

• Does not stimulate insulin secretion, minimizing the risk of hypoglycemia

Combination Effect:

• Provides complementary blood sugar control

• Improves both fasting and postprandial glucose levels

• Supports weight neutrality and cardiovascular safety

Dosage and Administration

• The usual recommended dose is 1 tablet twice daily with meals, or as prescribed by the physician

• Swallow the tablet whole with water; do not crush or chew

• Dosage adjustment may be required in renal or hepatic impairment

• Therapy should be combined with lifestyle modifications, including diet and exercise

• Regular monitoring of blood glucose and HbA1c is recommended to evaluate efficacy

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Use with caution in patients with renal impairment or risk of lactic acidosis

• Monitor kidney function periodically

• Not recommended for type 1 diabetes or diabetic ketoacidosis

• May interact with other antidiabetic drugs, requiring careful dose adjustment

• Advise patients to recognize signs of hypoglycemia and hyperglycemia

Possible Side Effects

Common side effects may include:

• Gastrointestinal: nausea, vomiting, diarrhea, abdominal discomfort

• Headache

• Nasopharyngitis or mild upper respiratory symptoms

• Rarely, lactic acidosis (life-threatening, more likely in renal impairment)

Hypoglycemia risk increases when combined with sulfonylureas or insulin.

Contraindications

• Severe renal impairment or end-stage renal disease

• Known hypersensitivity to Linagliptin, Metformin, or any component of the formulation

• Acute or chronic metabolic acidosis, including diabetic ketoacidosis

Pregnancy & Lactation

• Use only if clearly indicated and under medical supervision

• Metformin may be continued during pregnancy; consult a healthcare professional

• Safety of Linagliptin in pregnancy is not established

Storage

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.